Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed.

Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed.

Compositions for transdermal delivery of an active agent and methods for using such compositions are described herein.

The purpose of this invention is to find a novel fragrance component effective for prevention or control of swelling, lymphedema, skin aging or obesity from the viewpoint of activation of lymph vessel function by promotion of the expression of VEGFC. This invention provides a swelling improving agent, lymph vessel activator and VEGFC production promoter characterized by containing one or a plurality of components selected from the group consisting of rose oxide, citronellyl acetate and niaouli oil.

Improvements applied to a textile product, and more particularly wherein the improved product is a woven textile product—fabric containing bioceramic microparticles embedded into the fibers thereof with high capacity of irradiation in the infrared region, provided to be used both in humans and animals, more particularly the invention is related to a textile product containing bioceramic microparticles with high capacity of infrared irradiation which, in contact with the heat of the human body, is capable of transmitting infrared radiation in the range between 3 μm and 14.8 μm, preferentially in the 14.8 micron range, said infrared radiation at this wavelength being capable of regulating the blood microcirculation, as the result of its high protection, the blood microcirculation being the nervous center of human and/or animal metabolism.

The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.

The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.

The invention pertains to a pharmaceutical composition for topical administration, comprising a prodrug for an agonist and/or an antagonist for an adrenergic receptor, wherein the prodrug has an octanol/water partition coefficient of at least 0, for use in a method of shaping a mammalian body by modulation of subcutaneous fat tissue. The invention further pertains to cosmetic and therapeutic application of such prodrugs, such as their use in methods of shaping a mammalian body by locally modulating subcutaneous fat tissue. The invention also pertains to the prodrugs themselves, as well as to methods of making these prodrugs.

The invention pertains to a pharmaceutical composition for topical administration, comprising a prodrug for an agonist and/or an antagonist for an adrenergic receptor, wherein the prodrug has an octanol/water partition coefficient of at least 0, for use in a method of shaping a mammalian body by modulation of subcutaneous fat tissue. The invention further pertains to cosmetic and therapeutic application of such prodrugs, such as their use in methods of shaping a mammalian body by locally modulating subcutaneous fat tissue. The invention also pertains to the prodrugs themselves, as well as to methods of making these prodrugs.

Disclosed is the non-therapeutic use, as a DNA-demethylating agent, of at least one organometallic compound including an iron atom bound to two terpyridine groups. Further disclosed are method related to applying such agent as medicine.